Abbott Laboratories Corporation

Abbott Japan Co. Ltd.

Abbvie Inc.

Abbott Point of Care Inc.

Abbott Japan LLC

Barry Lee Dowell

Qiaoqiao Ruan

Toru Yoshimura

David J Hawksworth

Anthony Scott Muerhoff

Robert N Ziemann

Larry G Birkenmeyer

Susan E Brophy

Bryan C Tieman

Joseph P Skinner

Bailin Tu

Sergey Y Tetin

Carol S Ramsay

Cheng Zhao

Susan Gayda

Carolyn J Strobel

Philip M Hemken

Gangamani S Beligere

Allan H Smith

Kenju Fujita

Susan B O'Morchoe

Debra B Alexander

Carol A King

Dominique P Bridon

Xiaoxing Qiu

John Campbell

Eisaku Yoshida

Kim Sverker Pettersson

James Smith

Richard R Lesniewski

Wenda Weiss

Linda Nguyen

Dimitrí Semizarov

Mauno Antero Vihinen

Timo Petteri Piironen

Hans Lilja

Evelyn M McKeegan

Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.

Anti-GP73 monoclonal antibodies and methods of obtaining the same

Provided herein are assays and kits useful for avoiding 'prozone phenomenon' or 'hook effect' and which expand the range of accurately measurable analyte concentrations.

Assay with increased dynamic range

To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample. By using a blood sample in a condition in which a blood coagulation factor is not activated is used as a sample, the degradation of ProGRP is suppressed, whereby it is possible to store a sample for a long period of time and to improve the accuracy of an assay.

Immunoassay method for pro-gastrin-releasing peptide

The present invention relates to systems and methods for the rapid in situ determination of the existence of a hook effect and expansion of the dynamic range of a point of care immunoassay. For example, a system for identifying a hook effect and expanding the dynamic range of an immunoassay is provided that may include a primary sensor having first immobilized antibodies that may be configured to generate a first signal based on a presence or absence of a target analyte in a sample. The system may further include an attenuated sensor having second immobilized antibodies at a reduced concentration relative to a concentration of the first immobilized antibodies on the primary sensor and that may be configured to generate a second signal based on the presence or absence of the target analyte in the sample. The system may further include a processor configured to determine a presence of a hook effect in the immunoassay based on relative values of the first and second signals and optionally determine the target analyte concentration of the sample.

Apparatus and method for identifying a hook effect and expanding the dynamic range in point of care immunoassays

The present disclosure relates to antibodies and immunoassay methods for use in the diagnosis, treatment and prevention of hepatocellular carcinoma (HCC), liver cancer and related conditions.

Antibodies relating to PIVKA-II and uses thereof

Disclosed are methods for classifying a patient with cancer as a candidate for therapy with a Bcl-2 family inhibitor comprising determining the level of at least one biomarker in a sample and comparing the biomarker level to a threshold level. Also described are methods for identifying classes of patients having a refractory cancer for second-line therapy comprising a Bcl-2 family inhibitor, where the method comprises determining the level of at least one biomarker in a sample and comparing the biomarker level to a threshold level.

Biomarkers for identifying patient classes

The present invention relates to antibodies that may be used, for example, in the diagnosis, treatment and prevention of haepatocellular carcinoma (HCC), liver cancer and related conditions.

Antibodies relating to PIVKAII and uses thereof

The present invention relates to peptides which may be used, for example, in the detection of free and complexed Prostate Specific Antigen and thus in the diagnosis of prostate cancer.

Prostate specific antigen peptides and uses thereof

The present invention relates to the field of cancer immunoassay. Specifically, a new immunoassay method for prostate specific antigen (PSA) is presented. Also presented is a complex which resembles a complex of PSA and .alpha.-antichymotrypsin (ACT) that can be used as a calibrator or control in an immunoassay for PSA. Further presented is a method for fractionating polyclonal antibodies, to PSA, into those which bind epitopes that are masked by the binding of PSA to ACT and those which do not bind such epitopes.

Immunoassays for prostate specific antigen

Growing community of inventors

Mundelein, IL, United States of America

Barry Lee Dowell